Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2231 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2231 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Oncology
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Treatment being tested: Ifinatamab deruxtecan (I-DXd), a novel antibody-drug conjugate targeting DLR3, is being evaluated for efficacy and safety in patients with advanced or…
04 Aug 2026 NCT06644781
● Recruiting Phase I / Phase II
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
Early-stage trial testing a new drug (ALE1) for safety and effectiveness in healthy people and those with hypophosphatasia.
03 Aug 2026 NCT07179640
● Recruiting Phase III
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
Apraglutide versus placebo for short bowel syndrome: 24-week trial testing effectiveness and safety in 124 patients.
03 Aug 2026 NCT07742735
active not recruiting Phase III Diabetes / Metabolic
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Cagrilintide (new injection) versus placebo tested for weight loss in overweight people with type 2 diabetes over 18 months.
03 Aug 2026 NCT07220759
● Recruiting Gastroenterology
Dietary Supplements and Middle Aged Women (Collagen & Omega)
Collagen and omega supplements tested over 8 weeks to see if they improve joint pain, fatigue, sleep, and strength in middle-aged women.
03 Aug 2026 NCT07740967
active not recruiting Phase I / Phase II Oncology
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
A radioactive drug combined with standard chemotherapy and immunotherapy is being tested in newly diagnosed extensive small cell lung cancer.
03 Aug 2026 NCT05142696
● Recruiting Oncology
Patient and Provider Perspectives on Genetic Risk Profiling
What is being tested: Patient and healthcare provider perspectives on the clinical utility and practical application of genetic risk profiling when integrated into routine…
03 Aug 2026 NCT07741929
● Recruiting Gastroenterology
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
What is being tested: This study establishes a reference framework for outcomes following machine-preserved liver transplantation across Europe, addressing the clinical need for standardized…
03 Aug 2026 NCT07585890
● Recruiting Phase III Oncology
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Treatment being tested: Combination therapy of belzutifan (a HIF-2α inhibitor) and zanzalintinib (a VEGFR/TKI) in patients with recurrent advanced renal cell carcinoma following prior…
03 Aug 2026 NCT07227402
● Recruiting Cardiology / Cardiovascular
Feasibility and Acceptability of Isometric Exercise and Lifestyle Change for the Management of Hypertension
What is being tested: A home-based isometric exercise programme combined with lifestyle change advice as a potential management strategy for hypertension, with evaluation of…
03 Aug 2026 NCT07213479
● Recruiting Phase II Oncology
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Intervention: Povetacicept is being tested as a novel treatment for generalized myasthenia gravis (gMG), with evaluation focused on its pharmacodynamic effects, safety profile, and…
03 Aug 2026 NCT07501702
● Recruiting Phase III
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Upadacitinib tablets tested for safety and effectiveness in treating severe hair loss caused by immune system attack in adolescents and adults.
31 Jul 2026 NCT06012240
● Recruiting Phase III Rheumatology
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Trial comparing risankizumab versus adalimumab injections for childhood psoriatic arthritis, measuring safety and disease improvement over 124 weeks.
31 Jul 2026 NCT06100744
active not recruiting Phase III
Nipocalimab in Moderate to Severe Sjogren’s Disease
Nipocalimab injection appears safe and effective for treating moderate to severe Sjögren's disease symptoms.
31 Jul 2026 NCT06741969
active not recruiting Phase I / Phase II Oncology
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Trial testing combined amivantamab and capmatinib drugs in advanced lung cancer with specific genetic mutations to find safe, effective doses.
31 Jul 2026 NCT05488314
● Recruiting Phase III Rheumatology
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Nipocalimab reduced disease activity better than placebo in moderate-to-severe lupus patients.
31 Jul 2026 NCT07438496
active not recruiting Phase III Oncology
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Nivolumab versus placebo to prevent cancer recurrence in patients with liver cancer after surgery or ablation.
31 Jul 2026 NCT03383458
active not recruiting Phase I
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
New drug JNJ-90009530 tested in patients with hard-to-treat B-cell lymphoma to find safe doses and whether it works.
31 Jul 2026 NCT05784441
● Recruiting Gastroenterology
An Exploration of Family Centred Care (FCC) in UK Inpatient Wards
Study explores how patients, families, and nurses experience family involvement in hospital care and identifies culturally sensitive communication approaches.
31 Jul 2026 NCT07740369
● Recruiting Oncology
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
What is being tested: The role of fructose as a metabolic and inflammatory driver in MASH (metabolic dysfunction-associated steatohepatitis), investigating whether fructose specifically contributes…
31 Jul 2026 NCT07013916
● Recruiting Phase IV Oncology
Fibrosis Lessens After Metabolic Surgery
What is being tested: The trial evaluates whether metabolic surgery (such as bariatric procedures) can reduce liver fibrosis in patients with metabolic dysfunction-associated steatotic…
31 Jul 2026 NCT06374875
● Recruiting Phase II Rheumatology
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Treatment being tested: MK-8690, a novel therapeutic agent, is being evaluated for efficacy and safety in treating moderately to severely active ulcerative colitis, with…
31 Jul 2026 NCT07463183
● Recruiting Cardiology / Cardiovascular
The Oxford Risk Factors And Non-Invasive Imaging Study
What is being tested: ORFAN is developing and validating novel biomarkers for cardiometabolic disease risk by combining CT imaging data with biological material collection…
31 Jul 2026 NCT05169333
● Recruiting Oncology
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
What is being tested: The study investigates genetic mutations and biological factors in cancer cells that predict treatment response and resistance in adults with…
31 Jul 2026 NCT07737509
● Recruiting Phase III Oncology
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
What is being tested: TAR-210 (a novel therapeutic agent) is being compared against standard intravesical chemotherapy in BCG-treated patients with high-risk non-muscle-invasive bladder cancer…
31 Jul 2026 NCT06919965
active not recruiting Phase III Infectious Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
Two-drug long-acting injections (cabotegravir and rilpivirine) monthly maintain HIV suppression as well as daily tablets in treatment-experienced patients.
30 Jul 2026 NCT02938520
active not recruiting Diabetes / Metabolic
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
SPYRAL AFFIRM: One-sentence summary Renal denervation using Symplicity Spyral safely and effectively lowers blood pressure in patients with uncontrolled hypertension.
30 Jul 2026 NCT05198674
active not recruiting Phase III Oncology
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
New antibody-drug conjugate T-DXd, with or without pertuzumab, compared to standard chemotherapy for HER2-positive advanced breast cancer.
30 Jul 2026 NCT04784715
● Recruiting Phase I Oncology
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Drug Being Tested: ART0380, a novel therapeutic agent being evaluated for safety, tolerability, and efficacy in patients with advanced or metastatic solid tumors, with…
30 Jul 2026 NCT04657068
● Recruiting Oncology
SpaceOAR Post-Market Registry Study
What is being tested: Long-term safety profile of rectal hydrogel spacers (SpaceOAR) used during radiotherapy for prostate cancer, addressing regulatory concerns about limited post-market…
30 Jul 2026 NCT07300631
● Recruiting Oncology
Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery
What is being tested: Novel dual optical imaging systems combining OCT-Raman spectroscopy (for lumpectomy specimens) and autofluorescence-Raman spectroscopy (for sentinel lymph nodes) to provide…
30 Jul 2026 NCT06977698
● Recruiting Phase II Respiratory / COPD / Asthma
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
OATD-01 is being tested as a potential therapeutic agent for active pulmonary sarcoidosis in a Phase 2 randomized controlled trial, with assessment of efficacy,…
30 Jul 2026 NCT06205121
● Recruiting Respiratory / COPD / Asthma
Physical Activity Promotion and Clinical Remission in Severe Asthma
What is being tested: A structured physical activity promotion programme combined with tezepelumab (a biologic therapy) versus standard care alone, to determine if exercise…
30 Jul 2026 NCT07735494
● Recruiting Cardiology / Cardiovascular
Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases
Device being tested: The Occlutech® mVSD device for percutaneous (catheter-based) closure of hemodynamically or clinically significant muscular ventricular septal defects (mVSD) as an alternative…
30 Jul 2026 NCT05329350
● Recruiting Cardiology / Cardiovascular
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
What is being tested: The Occlutech PDA Occluder device and delivery system for transcatheter closure of patent ductus arteriosus (PDA), with evaluation of both…
30 Jul 2026 NCT05264753
● Recruiting Phase II Oncology
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
What is being tested: Subcutaneous zilucoplan, a complement C5 inhibitor, is being evaluated for its pharmacokinetics, safety, tolerability, immunogenicity and clinical activity in pediatric…
30 Jul 2026 NCT06055959
active not recruiting Phase III
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
Trial testing whether leriglitazone drug slows cerebral adrenoleukodystrophy progression in adult men.
29 Jul 2026 NCT05819866
active not recruiting Phase II Oncology
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Trial testing TAR-200 drug alone or combined with cetrelimab immunotherapy versus cetrelimab alone for bladder cancer resistant to standard treatment.
29 Jul 2026 NCT04640623
active not recruiting Phase III Oncology
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Pembrolizumab plus chemotherapy before surgery, then pembrolizumab alone after surgery, improves survival in resectable lung cancer.
29 Jul 2026 NCT03425643
active not recruiting Infectious Disease
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
A rapid urine test accurately identifies bacteria causing urinary tract infections and detects antibiotic resistance.
29 Jul 2026 NCT06824129
● Recruiting
EMBRACE Tremor BiFUS
Staged bilateral focused ultrasound thalamotomy added to medication improves tremor control compared to medication alone in patients with prior unilateral treatment.
29 Jul 2026 NCT06974916
active not recruiting Phase III Oncology
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Olaparib vs placebo as maintenance therapy after chemotherapy in BRCA-mutated ovarian cancer patients.
29 Jul 2026 NCT01874353
active not recruiting Phase III Oncology
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Sacituzumab govitecan improves survival compared to standard treatment in advanced endometrial cancer patients previously treated with chemotherapy and immunotherapy.
29 Jul 2026 NCT06486441
● Recruiting Cardiology / Cardiovascular
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
What is being tested: Daily Low-methoxy (LM) pectin supplementation (a dietary polysaccharide from citrus peels) to determine whether it reduces systemic inflammation, modifies gut…
29 Jul 2026 NCT07093346
● Recruiting Phase III Respiratory / COPD / Asthma
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
What is being tested: Long-term safety, tolerability, and efficacy of seralutinib, an orally inhaled therapeutic agent, in patients with pulmonary arterial hypertension (PAH) who…
29 Jul 2026 NCT06274801
● Recruiting Oncology
BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer
What is being tested: A personalised decision support intervention (BeSpoke) that provides tailored treatment counselling to help newly diagnosed prostate cancer patients make informed…
29 Jul 2026 NCT07135271
● Recruiting Phase I Oncology
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
What is being tested: MCLA-158, a bispecific antibody, is being evaluated as a single-agent treatment in patients with advanced solid tumors, with completed dose…
29 Jul 2026 NCT03526835
active not recruiting Phase III Oncology
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
New drug volrustomig plus chemotherapy compared with pembrolizumab plus chemotherapy for advanced lung cancer with low PD-L1 levels.
28 Jul 2026 NCT05984277
active not recruiting Cardiology / Cardiovascular
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
Impella heart pump during high-risk coronary angioplasty improves symptoms and heart function in patients with weak hearts.
28 Jul 2026 NCT04763200
active not recruiting Phase III Oncology
Phase III Study of AK112 for NSCLC Patients
AK112 plus chemotherapy improved outcomes in advanced lung cancer patients whose tumours had stopped responding to targeted therapy.
28 Jul 2026 NCT06396065